Exit / M&A
Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.